Zynerba Pharmaceuticals Overview
Latest ROE for Zynerba Pharmaceuticals: -127.53% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-127.53%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ZYNE is -127.53%. That is below the Healthcare sector average of 22.76%. Investors often review this figure alongside Zynerba Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ZYNE currently prints -127.53% for ROE, while the sector average sits near 22.76%. That is roughly 660.2% below the sector mean. Large gaps often invite a closer look at Zynerba Pharmaceuticals's growth, margins, and balance sheet.
Return on Equity shows how effectively Zynerba Pharmaceuticals converts resources into returns. At -127.53%, ZYNE may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ZYNE's ROE (-127.53%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Zynerba Pharmaceuticals's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
